UPDATE: Credit Suisse Reiterates On BIND Therapeutics After AMGN Declines Option On Accurin Technology

By: via Benzinga
In a report published Thursday, Credit Suisse analyst Jason Kantor reiterated an Outperform rating on BIND Therapeutics (NASDAQ: BIND), ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.